Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Prostate Cancer

Prostate Cancer

18 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Prostate Cancer

669 trials tracked for Prostate Cancer: 125 in phase 3 or 4 and 47 with published results. The most-cited published study has 1650 citations.

669Trials tracked
125Phase 3 & 4
0Recruiting
47With published results
Phase distribution
Phase 4 15 Phase 3 110 Phase 2 350 Phase 1 43 Other / NA 151
  1. Phase 3 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Completed · 1,650 cited
  2. Phase 3 Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence Completed · 784 cited
  3. Phase 3 Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed · 700 cited
  4. Phase 3 Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy Completed · 658 cited
  5. Phase 3 Radiation Therapy in Treating Patients With Stage II Prostate Cancer Completed · 628 cited
  6. Phase 3 SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Completed · 568 cited
Show 44 more trials
  1. Phase 3 A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer Completed · 431 cited
  2. Phase 3 Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms Completed · 395 cited
  3. Phase 3 Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Completed · 356 cited
  4. Phase 3 Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients Completed · 336 cited
  5. Phase 3 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed · 333 cited
  6. Phase 3 Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Completed · 288 cited
  7. Phase 3 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 Completed · 247 cited
  8. Phase 3 Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Completed · 230 cited
  9. Phase 3 Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer. Completed · 230 cited
  10. Phase 3 FACBC Outcomes for Post Prostatectomy Completed · 182 cited
  11. Phase 4 Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients Completed · 171 cited
  12. Phase 3 Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Completed · 138 cited
  13. Phase 3 Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer Completed · 134 cited
  14. Phase 3 Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer Completed · 132 cited
  15. Phase 3 Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) Completed · 131 cited
  16. Phase 3 Radiation Therapy in Treating Patients With Stage II Prostate Cancer Completed · 118 cited
  17. Phase 3 S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer Completed · 111 cited
  18. Phase 3 Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer Completed · 107 cited
  19. Phase 3 Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. Completed · 90 cited
  20. Phase 3 Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy Completed · 62 cited
  21. Phase 3 Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) Completed · 49 cited
  22. Phase 3 Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Completed · 41 cited
  23. Phase 3 Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer Completed · 38 cited
  24. Phase 3 S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Completed · 37 cited
  25. Phase 3 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment Completed · 31 cited
  26. Phase 3 Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Completed · 29 cited
  27. Phase 3 A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) Completed · 29 cited
  28. Phase 3 A Study of Degarelix in Patients With Prostate Cancer Completed · 25 cited
  29. Phase 3 Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer Completed · 25 cited
  30. Phase 3 Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Completed · 20 cited
  31. Phase 3 Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer Completed · 20 cited
  32. Phase 3 PROvenge Treatment and Early Cancer Treatment Completed · 18 cited
  33. Phase 3 Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer Completed · 17 cited
  34. Phase 4 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed · 13 cited
  35. Phase 4 A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients Completed · 9 cited
  36. Phase 3 Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence Completed · 6 cited
  37. Phase 3 Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Completed · 2 cited
  38. Phase 3 A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Completed · 2 cited
  39. Phase 3 Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance Completed
  40. Phase 3 Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Completed
  41. Phase 3 Study of Diagnostic Performance of [18F]CTT1057 in BCR Completed
  42. Phase 4 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed
  43. Phase 4 Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery Completed
  44. Phase 4 A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients. Completed

Showing the 50 most-cited and recently-updated of 669 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Arecoline may upregulate androgen receptor in prostate cancer cells, integrative analysis suggests
Drug Pipeline Guideline
Arecoline may upregulate androgen receptor in prostate cancer cells, integrative analysis suggests Arecoline Linked to Prostate Cancer Pathways in Lab Study
This guideline-based integrative analysis combined computational and in vitro methods to explore arecoline's potential link to prostate canc…
New laboratory analysis identifies a potential link between arecoline and specific molecular pathways related to prostate cancer.
Frontiers Jun 8, 2026
PSA-based prostate cancer screening reduces mortality but increases diagnoses
Oncology Meta-analysis
PSA-based prostate cancer screening reduces mortality but increases diagnoses New review shows prostate cancer screening might save lives but also finds more diagnoses
This meta-analysis of six randomized trials with 789,086 men in Europe and North America found PSA screening likely reduces prostate cancer-…
A large study of nearly eight hundred thousand men found that checking for prostate cancer with blood tests likely lowers death rates from t…
May 15, 2026
Polygenic Risk Score Ties to Prostate Cancer Aggressiveness
Genetics & Precision Medicine RCT
Polygenic Risk Score Ties to Prostate Cancer Aggressiveness New Genetic Score Predicts Aggressive Prostate Cancer in Men
A polygenic risk score (PRSagg) was associated with higher-grade prostate cancer and unfavorable outcomes during active monitoring, suggesti…
A new genetic test could help men with prostate cancer know if their tumor is likely to become aggressive, guiding them toward more urgent t…
medRxiv May 15, 2026
NeuroSAFE-guided robot-assisted prostatectomy improves erectile function and continence in men
Oncology Meta-analysis
NeuroSAFE-guided robot-assisted prostatectomy improves erectile function and continence in men New surgical method cuts cancer risk and restores function after prostate surgery
This systematic review and meta-analysis of 22,183 men undergoing robot-assisted radical prostatectomy found that NeuroSAFE guidance signifi…
A real-time tissue check during prostate surgery may restore bladder control and sexual function faster while still removing all cancer.
May 13, 2026
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Urology RCT
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
May 7, 2026
Review of bibliometric data shows growing research interest in macrophage polarization strategies for prostate cancer since 2015
Infectious Disease Sys. Review
Review of bibliometric data shows growing research interest in macrophage polarization strategies for prostate cancer since 2015 Your Body's Immune Cells Could Fight Prostate Cancer Better
This bibliometric and visual analysis review examines publications related to macrophage polarization and activation in prostate cancer. The…
• Scientists reprogrammed immune cells to attack prostate tumors • Helps men with stubborn advanced prostate cancer • Still in early clinica…
Frontiers May 7, 2026
MRI-RSI changes during neoadjuvant ADT and radiotherapy in men with high-risk localized prostate cancer
Urology Phase II
MRI-RSI changes during neoadjuvant ADT and radiotherapy in men with high-risk localized prostate cancer Early MRI scans shrink after treatment to help spot prostate cancer recurrence sooner
This prospective phase II trial protocol reports early results from 97 men with unfavorable-intermediate-risk or high-risk localized prostat…
New MRI scans taken before and during treatment for prostate cancer show clear shrinkage that could help doctors target the tumor more accur…
medRxiv Apr 30, 2026
Machine learning quantification of Gleason Pattern 4 showed higher discrimination for adverse pathology than grade group in prostate cancer
Oncology Cohort
Machine learning quantification of Gleason Pattern 4 showed higher discrimination for adverse pathology than grade group in prostate cancer AI Measures Prostate Cancer Risk More Accurately Than Standard Methods
This proof-of-principle cohort study evaluated 726 patients with grade group 2-4 prostate cancer on systematic biopsy who underwent radical …
A new AI tool can spot dangerous prostate cancer patterns better than current grading, offering men a clearer picture of what to expect afte…
medRxiv Apr 24, 2026
Image-guided radiotherapy dose intensification for intermediate- or high-risk prostate cancer
Urology RCT
Image-guided radiotherapy dose intensification for intermediate- or high-risk prostate cancer New prostate cancer radiation targets only the tumor, not the whole gland
This is a phase II randomized controlled trial protocol for patients with intermediate- or high-risk prostate cancer planning radiotherapy.
This study tests a smarter way to deliver radiation—focusing the dose on the tumor while protecting the rest of the prostate, which could me…
medRxiv Apr 23, 2026
ML-driven decision aid reduces decisional conflict in prostate cancer screening discussions compared to standard education
Oncology RCT
ML-driven decision aid reduces decisional conflict in prostate cancer screening discussions compared to standard education How AI Helps Older Men Decide on Prostate Cancer Tests
This randomized controlled trial evaluated a web-based, machine learning-driven decision aid versus video-based education in middle-aged and…
A new digital tool helps older men make clearer choices about prostate cancer tests by reducing their worry and confusion.
Apr 14, 2026
Systematic review finds PSA screening reduces prostate cancer mortality but increases overdiagnosis and false positives
Primary Care & Family Medicine Sys. Review
Systematic review finds PSA screening reduces prostate cancer mortality but increases overdiagnosis and false positives A New Prostate Cancer Check Could Save Lives—With Fewer False Alarms
A systematic review and meta-analysis of men not known to be at high risk for prostate cancer found that PSA-based screening likely reduces …
A new analysis of nearly a million men shows adding an MRI after a high PSA test drastically cuts false alarms and unnecessary biopsies.
medRxiv Apr 11, 2026
Serum triglyceride levels show no relationship with prostate cancer risk in a meta-analysis of Chinese men
Oncology Meta-analysis
Serum triglyceride levels show no relationship with prostate cancer risk in a meta-analysis of Chinese men High Triglycerides Do Not Raise Prostate Cancer Risk in Chinese Men
This meta-analysis evaluated the association between serum triglyceride levels and prostate cancer risk among 4,732 Chinese men.
High triglycerides do not increase prostate cancer risk in Chinese men, challenging earlier Western-based assumptions.
Frontiers Apr 11, 2026

Questions about Prostate Cancer

Can dose intensification improve outcomes for intermediate- or high-risk prostate cancer?

Yes, early evidence suggests dose intensification to visible tumors may improve outcomes for intermediate- or high-risk prostate cancer, but ongoing trials will clarify safety and efficacy.

Full answer →
Is there more research on macrophage polarization for prostate cancer since 2015?

Yes, research on macrophage polarization in prostate cancer has grown significantly since 2015, with studies exploring its role in tumor progression and therapy resistance.

Full answer →
Can enzalutamide plus ADT improve survival for metastatic hormone-sensitive prostate cancer?

Yes, enzalutamide plus ADT significantly improves survival in metastatic hormone-sensitive prostate cancer, with a 34% reduction in risk of death and a 5-year survival rate of 66% versus 53% with ADT alone.

Full answer →

All Prostate Cancer Articles